Institution Directory

Clinical trials at Memorial Sloan Kettering Cancer Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1675

Shown on this page

Current sort

Live official records

Conditions: Prostate Cancer
Interventions: Ipilimumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 3
States / cities: Evanston, Illinois • New York, New York • Portland, Oregon

Conditions: Malignant Biliary Obstruction
Interventions: FACT-Hep; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more

Conditions: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma
Interventions: Zilovertamab vedotin; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 6 Months to 25 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 17
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 14 more

Conditions: Acute Myeloid Leukemia
Interventions: Ivosidenib, Azacitidine, Venetoclax; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Acute Lymphocytic Leukemia, Lymphoma
Interventions: Biological/Genetically Modified T cells, Cyclophosphamide-based chemotherapy; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Ovarian Cancer
Interventions: Questionnaire, Interview; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2026
U.S. locations: 5
States / cities: West Hollywood, California • Iowa City, Iowa • New York, New York + 2 more

Conditions: Ovarian Cancer, Ovarian Cancer Recurrent
Interventions: COM701, Normal Saline; Drug
Lead sponsor: Compugen Ltd; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: Augusta, Georgia • Chicago, Illinois • Warrenville, Illinois + 10 more

Conditions: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Interventions: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, Rituximab and Lenalidomide, rituximab and bendamustine, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, gemcitabine and oxaliplatin, Epcoritamab, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate; Drug · Biological
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 543 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more

Conditions: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions: Tazemetostat, Placebo oral tablet, Lenalidomide, Rituximab; Drug · Combination Product
Lead sponsor: Epizyme, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 57
States / cities: Mobile, Alabama • Tucson, Arizona • Cerritos, California + 47 more

Conditions: Multiple Myeloma, Hypogammaglobulinemia, Hypogammaglobulinemia, Acquired
Interventions: IgPro20; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 9
States / cities: Atlanta, Georgia • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Newly Diagnosed Cancer Patients
Interventions: Hospital Counseling + Nicotine Replacement Therapy. questionaires, Hospital Counseling + Nicotine Replacement + Presurgical Scheduled Reduced Smoking, questionaires; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions: Questionnaires, Interviews, 30-minute telephone or videoconference sessions; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

About this Memorial Sloan Kettering Cancer Center institution page

What this page lists: ClinicalTrials.gov records that list Memorial Sloan Kettering Cancer Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Memorial Sloan Kettering Cancer Center

Filter and sort this campus

Live official records

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

A Quality of Life Study in Patients Undergoing Percutaneous Biliary Drainage

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Smoking Cessation Intervention for Cancer Patients

A Study of Mental Health Care in People With Cancer

About this Memorial Sloan Kettering Cancer Center institution page